To Explore the Value of New MR Technology in Non-invasive Quantitative Assessment of Systemic Metabolism, Disease Status and Prognosis in Patients With Metabolic-Associated Fatty Liver Disease

ConditionsNonalcoholic Fatty Liver Disease Metabolic-associated Fatty Liver Disease

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

AgeNot listed

SponsorTongji Hospital

About this trial

The purpose of this study is to explore the value of new MR technology in assessing the systemic metabolism, disease status, and prognostic risk of metabolism-related fatty liver disease. By obtaining clinical, imaging, laboratory examination and pathological data of metabolism-related fatty liver disease, image processing software is used to analyze the images, explore the relationship between imaging parameters, body composition and metabolic diseases and metabolism-related fatty liver disease, and achieve non-invasive diagnosis, efficacy evaluation, and prognosis prediction of metabolism-related fatty liver disease. Thereby guiding clinical treatment and improving the prognosis and quality of life of patients with metabolism-related fatty liver disease

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Patients with MR examination are clinically suspected or diagnosed with metabolism-related fatty liver disease;

Age/gender: unlimited;

Patients who voluntarily participate in clinical trials and sign written subject informed consent

Disqualifiers

Clinical suspicion or diagnosis of metabolism-related fatty liver disease and having been prescribed an MR examination;

Voluntarily participation in the study and provision of written informed consent.

Trial population

Clinically suspected or diagnosed metabolically related fatty liver disease patients

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

500 Participants

are grouped into 1 trial group

Group A: Metabolic-Associated Fatty Liver Disease patients

Trial outcomes

Primary outcomes

Sensitivity (sensitivity) and specificity (specificity) of MR sequence measurement results vs. liver biopsy (gold standard) translated into English

Time frame

From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 120 months

Secondary outcomes

Time from baseline MR scan to development of liver cirrhosis, liver decompensation event, liver cancer, death

Time frame

From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 120 months

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Tongji Hospital

Lead sponsor

Source ClinicalTrials.gov

Apply now